BioCentury | Jun 6, 2020
Finance

Sale of up to 19 Woodford stakes chips away at firm’s remaining portfolio

Backers of a fund formerly managed by fallen star investor Neil Woodford are finally getting another chunk of their money back, albeit for pence on the pound. Link Fund Solutions Ltd. announced Friday that it...
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

Private biotech companies held by funds formerly managed by Neil Woodford haven’t rid themselves of the debacle that led to the star British investor’s demise. According to a report in The Times that did not...
BC Extra | Jan 3, 2020
Financial News

Jan. 3 Financial Quick Takes: Black Diamond plots IPO; plus Oxford Nanopore, CF PharmTech, Mygene and Zerun

Black Diamond seeking NASDAQ listing  Tumor-agnostic precision oncology company Black Diamond Therapeutics Inc. filed for an IPO on NASDAQ worth up to $100 million. Shepherded since 2017 by lead investor Versant Ventures, the company is...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

Perhaps the greatest sign of robustness of the U.K. biotech sector is that it barely budged on the news this week of Neil Woodford’s demise. Woodford’s struggles came to an acrimonious and swift end as...
BC Extra | Oct 15, 2019
Financial News

Woodford flagship fund implodes as star fund manager axed

Neil Woodford’s struggles have come to an acrimonious end as the once vaunted British investor has been removed as fund manager of his firm’s flagship fund, Woodford Equity Income Fund, which is to be shuttered...
BC Extra | Jul 19, 2019
Financial News

Big discounts likely as auction looms for Woodford assets

While Neil Woodford’s Woodford Investment Management is expected to go ahead with an auction of its private biotech holdings this month, three healthcare investors told BioCentury it isn’t a sure thing the fund will be...
BC Extra | Jun 28, 2019
Financial News

June 27 Financial Quick Takes: Esperion gets $125M from Oberland in funding deal for cholesterol candidates; plus Woodford, PanTheryx and Castle

Esperion, Oberland strike funding deal ahead of bempedoic acid launch  Esperion Therapeutics Inc. (NASDAQ:ESPR) forged a funding agreement with Oberland Capital tied to revenues from the sale of products containing the biotech's cholesterol-lowering candidate bempedoic...
BC Extra | Jun 5, 2019
Financial News

Woodford suspends trade in flagship fund as woes for U.K. fund manager mount

Woodford Investment Management has been hit by a pair of setbacks this week as the pressure mounts on the high-profile U.K. fund manager to deliver better returns to investors. On Monday, Woodford announced it suspended...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BC Week In Review | Oct 19, 2018
Financial News

Oxford Nanopore receives £50M investment from Amgen

Oxford Nanopore Technologies Ltd. (Oxford, U.K.) received an equity investment of £50 million ($65.6 million) on Oct. 18 from Amgen Inc. (NASDAQ:AMGN). Amgen's deCODE Genetics subsidiary uses Oxford Nanopore's nanopore-based DNA and RNA sequencing technology...
Items per page:
1 - 10 of 54
BioCentury | Jun 6, 2020
Finance

Sale of up to 19 Woodford stakes chips away at firm’s remaining portfolio

Backers of a fund formerly managed by fallen star investor Neil Woodford are finally getting another chunk of their money back, albeit for pence on the pound. Link Fund Solutions Ltd. announced Friday that it...
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

Private biotech companies held by funds formerly managed by Neil Woodford haven’t rid themselves of the debacle that led to the star British investor’s demise. According to a report in The Times that did not...
BC Extra | Jan 3, 2020
Financial News

Jan. 3 Financial Quick Takes: Black Diamond plots IPO; plus Oxford Nanopore, CF PharmTech, Mygene and Zerun

Black Diamond seeking NASDAQ listing  Tumor-agnostic precision oncology company Black Diamond Therapeutics Inc. filed for an IPO on NASDAQ worth up to $100 million. Shepherded since 2017 by lead investor Versant Ventures, the company is...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

Perhaps the greatest sign of robustness of the U.K. biotech sector is that it barely budged on the news this week of Neil Woodford’s demise. Woodford’s struggles came to an acrimonious and swift end as...
BC Extra | Oct 15, 2019
Financial News

Woodford flagship fund implodes as star fund manager axed

Neil Woodford’s struggles have come to an acrimonious end as the once vaunted British investor has been removed as fund manager of his firm’s flagship fund, Woodford Equity Income Fund, which is to be shuttered...
BC Extra | Jul 19, 2019
Financial News

Big discounts likely as auction looms for Woodford assets

While Neil Woodford’s Woodford Investment Management is expected to go ahead with an auction of its private biotech holdings this month, three healthcare investors told BioCentury it isn’t a sure thing the fund will be...
BC Extra | Jun 28, 2019
Financial News

June 27 Financial Quick Takes: Esperion gets $125M from Oberland in funding deal for cholesterol candidates; plus Woodford, PanTheryx and Castle

Esperion, Oberland strike funding deal ahead of bempedoic acid launch  Esperion Therapeutics Inc. (NASDAQ:ESPR) forged a funding agreement with Oberland Capital tied to revenues from the sale of products containing the biotech's cholesterol-lowering candidate bempedoic...
BC Extra | Jun 5, 2019
Financial News

Woodford suspends trade in flagship fund as woes for U.K. fund manager mount

Woodford Investment Management has been hit by a pair of setbacks this week as the pressure mounts on the high-profile U.K. fund manager to deliver better returns to investors. On Monday, Woodford announced it suspended...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BC Week In Review | Oct 19, 2018
Financial News

Oxford Nanopore receives £50M investment from Amgen

Oxford Nanopore Technologies Ltd. (Oxford, U.K.) received an equity investment of £50 million ($65.6 million) on Oct. 18 from Amgen Inc. (NASDAQ:AMGN). Amgen's deCODE Genetics subsidiary uses Oxford Nanopore's nanopore-based DNA and RNA sequencing technology...
Items per page:
1 - 10 of 54